ANNX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Annexon expanded the Phase 3 vonaprument program in geographic atrophy by adding a Month 24 dual primary endpoint and launching an open-label extension studyAug 12, 2026
- Annexon reported rapid positive responses in the first U.S. and European GBS FORWARD patients treated with tanruprubartAug 6, 2026
- Annexon accelerated immunotherapy platform for neuroinflammatory diseases with 2026 milestonesJan 12, 2026
- Annexon announces completion of enrollment in pivotal Phase 3 ARCHER II trial of Vonaprument (formerly ANX007) for dry age-related macular degeneration with geographic atrophyJul 24, 2025
- Annexon announces presentations on the clinical advancement of Tanruprubart as the first potential targeted therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting.May 11, 2025